Pacira secures pain drug patent deal until 2030; shares up

Pacira Biosciences

07/04/2025 23:11

** Shares of drugmaker Pacira BioSciences PCRX.O rise 15% to $26.35 in extended trading

** PCRX says it has settled patent lawsuit with Fresenius Kabi over co's lead drug, Exparel

** Exparel is a drug that provides extended pain relief for up to 72 hours after a surgery

** Fresenius can sell limited amounts of generic Exparel starting early 2030

** The agreement allows Fresenius to sell without volume restrictions beginning in 2039 in the U.S.

** Brokerage Jefferies says it believes that the settlement is the "key to unlocking a re-rate in the multiple" and expects the co's revenue growth to "accelerate" with the removal of litigation overhang

** As of last close, stock up 21.6% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))